Development of a world-leading preclinical drug development company specialising in ophthalmology through innovative state-of-the-art preclinical models and expert provision of data interpretation.

糖尿病视网膜病变（DR）和年龄相关性黄斑变性（AMD），在这里被称为视网膜疾病，是全球视力丧失的主要原因，影响超过3亿人。目前视网膜疾病的治疗策略有限，有希望的药物在后期临床试验中疗效不佳。这是由于不良的临床前疾病模型。生物技术和制药公司超过50%的研究与开发（R&D）是外包的。在ICURe期间进行了广泛的市场研究，揭示了导致临床前药物开发不合格的关键因素。这些问题包括：过时和不适当的临床前模型；次优研究设计；缺乏协同数据解释；缺乏技术质量和糟糕的客户服务。MediNect建立在30年视网膜疾病临床前模型的密集研发基础上，提供针对目前市场上无法获得的疾病特征的最先进模型。MediNect拥有丰富的技术和解释知识，可提供最佳的研究设计，实用技术和数据解释。MediNect将作为一家公司，提供临床前药物开发的合作方式，在十种成熟的视网膜疾病模型和两种新模型中测试新药。根据行业标准验证，糖尿病黄斑缺血（DMI）和视网膜下纤维化（SRF）模型将分别用于更深入地了解针对晚期视网膜疾病的新型药物。我们的新模型优于目前使用复制早期疾病特征的模型的方法。此外，MediNect还拥有五种最先进的转基因模型和五种正在开发的模型，这些模型针对的是优于当前方法的视网膜疾病未满足的领域，这将巩固MediNect在眼科药物开发研究领域的市场领导者地位。MediNect由世界领先的专家和研究人员组成的团队将获得以客户为中心的黄金标准产品的赞誉，以提供肿瘤学- cro标准的通信流，研究计划，为药物开发提供更深入的见解。MediNect将帮助开发更好的视力恢复药物的迫切需求，帮助全球6000万患有晚期视网膜疾病的人。

Diabetic Retinopathy (DR) and Age-related macular degeneration (AMD), termed retinal disease herein, are the leading cause of vision loss worldwide, affecting over 300 million people. Current treatment strategies for retinal disease are limited, with poor efficacy observed in late-stage clinical trials of promising drugs. This is attributed to poor preclinical models of disease.Over 50% of the total research and development (R&D) by biotechnology and pharmaceutical companies is outsourced. Extensive market research conducted during ICURe, revealed key factors contributing to substandard preclinical drug development. These included: outdated and inappropriate preclinical models; suboptimal study design; a lack of collaborative data interpretation; a lack of technical quality and a poor customer service provision.MediNect builds on 30 years' intensive R&D of preclinical models in retinal disease to deliver state-of-the-art models that target disease features currently not available to the market. MediNect has a wealth of technical and interpretive know-how, which provides optimal study design, practical technique and data interpretation. MediNect will function as a company to offer a collaborative approach to preclinical drug development, with access to test novel drugs in ten well-established models of retinal disease and two novel models. Validated to industry standard, the diabetic macular ischaemia (DMI) and sub-retinal fibrosis (SRF) model will be used to give greater insight into novel drugs targeting late-stage retinal disease, respectively. Our novel models are superior to current methods that use models that replicate early-stage disease features.In addition, MediNect has a catalogue of five state-of-the-art genetically modified models and five in development that target unmet areas of retinal disease features that are superior to current methods and will cement MediNect's position as market leaders in ophthalmology drug development research.MediNect's team of world leading experts and researchers will be complimented by a gold-standard client-focused offering to deliver oncology-CRO standard communication streams, study planning providing greater insight into drug development.MediNect will help the urgent need for development of better vision-restoring drugs, helping 60 million people worldwide suffering from late-stage retinal disease.